SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collaboration and supply agreement with BayerProvided updated rinzimetostat combination data in post-abiraterone mCRPC and in post-AR inhibitor mCRPC, consisting of l…

ORIC

Related stories